Drug profiling in an immune cell-tumor spheroid co-culture model
|
|
- Della Norton
- 6 years ago
- Views:
Transcription
1 Oncology Drug Discovery Molecular Pharmacology Drug profiling in an immune cell-tumor spheroid co-culture model Silvia Goldoni, Investigator Novartis Institutes for Biomedical Research, Cambridge MA, USA 3D Tissue Models 2017
2 Outline of presentation Short introduction on 3D cultures for immuno-oncology studies Overview of our co-culture platform and characterization Immune profiling of a Novartis targeted therapy Effort to generate complex in vitro models Planned drug discovery efforts 2
3 Why 3D for immune profiling? Multicellular spheroids have enhanced immune suppressive phenotype compared to 2D tumor cell cultures : Lactate production Immune suppressive protein expression (IL8, VEGF, FasL) Limited antigen presentation Less sensitivity to IFNγ More physiological immune synapse Opportunity to study immune cell infiltration Cancer cells PBMCs 3
4 Co-culture overview Day -1: Tumor cell line seeding Day 0: add fresh PBMCs (CFSE-labeled) + treatment +/- stimulation 200um 100um Cells spontaneously gather in each micro-space poly-hema coating (low adherence surface) e.g. OvCar-8 OvCar8-mcherry PBMC Immune cell infiltration Cytokine release Tumor cell killing PBMC proliferation Day 5: data collection 4
5 Co-culture characterization T-cell activation: proliferation Immune cells- no tumor spheroid Immune cells- tumor associated Tumor spheroid size Proliferation Immune cell proliferation is not affected by soluble factors in the tumor line conditioned medium 5
6 T N F a [p g /m l] R A N T E S [p g /m l] IF N g [p g /m l] G M C S F [p g /m l] Co-culture characterization T-cell activation: cytokine release E lp la s ia P la te A lo n e T C e lls + S m a ll S p h e r e s T C e lls + M e d iu m S p h e r e s T C e lls + L a r g e S p h e r e s 0 E lp la s ia P la te A lo n e T C e lls + S m a ll S p h e r e s T C e lls + M e d iu m S p h e r e s T C e lls + L a r g e S p h e r e s E lp la s ia P la te A lo n e T C e lls + S m a ll S p h e r e s T C e lls + M e d iu m S p h e r e s T C e lls + L a r g e S p h e r e s 0 E lp la s ia P la te A lo n e T C e lls + S m a ll S p h e r e s T C e lls + M e d iu m S p h e r e s T C e lls + L a r g e S p h e r e s 6
7 Co-culture characterization Immune suppressive features Nat. Immunol IDO suppresses T-cell function promoting tumor immune tolerance 7
8 OvCar8 + PBMC OvCar8 d4 Co-culture characterization Immune suppressive features IDO1* ISH TGF-β ISH *Confirmed by qpcr 8
9 Immune profiling of a Novartis targeted therapy Testing the co-culture platform
10 Therapy enhances immune cell proliferation DMSO 0.5 µm 1 µm 10 µm Unstimulated Anti-CD3 stimulated* *Similar results observed in 4 of 5 donors tested CFSE= Carboxyfluorescein succinimidyl ester 10
11 Therapy enhances immune cell proliferation in co-culture DMSO Inactive scaffold (10 µm) Treatment* (10 µm) % proliferating cells *larger spheroids similar result with 1 µm 11
12 OvCar8 + PBMC OvCar8 d4 IDO1 expression is inhibited by treatment IDO1* ISH Treatment Co-culture 12
13 % Control Does treatment enhance immune cell-mediated tumor cell killing? Inactive scaffold Tool compound Treatment Concentration Concentration Concentration *Viability assay using CTG 3D at day 6 13
14 Absolute tumor cell counts Absolute tumor cell counts Treatment enhances immune cellmediated tumor cell killing k tumor cell counts 10k tumor cell counts unstimulated sol anti-cd3 unstimulated sol anti-cd DMSO 1uM MHP982 20uM LMD099 1uM TNO155 DMSO 1uM MHP982 20uM LMD099 1uM TNO155 DMSO 1uM MHP982 20uM LMD099 1uM TNO155 E Tumor only DMSO 1uM MHP982 20uM LMD099 1uM TNO155 DMSO 1uM MHP982 20uM LMD099 1uM TNO155 DMSO 1uM MHP982 20uM LMD099 1uM TNO155 Tumor-PBMC coculture E Tumor only E Co-culture Tumor-PBMC coculture Tumor only DMSO 1uM MHP982 20uM LMD099 1uM TNO155 DMSO 1uM MHP982 20uM LMD099 1uM TNO155
15 Chemoattractant cytokine IP10 is upregulated by treatment Co-culture PBMC + anti-cd3 Tumor spheroids Produced by monocytes, endothelial cells, fibroblasts in response to IFNγ and other cytokines Chemoattractant for anti-tumoral leukocytes (T, monocytes, NK cells) via interaction with CXCR3 15
16 CD45- CD45+ What cell types express IP10? PBMC Co-culture+DMSO Co-culture+DMSO +anti-cd3 Co-culture +anti-cd3 +Inactive 1 µm Co-culture +anti-cd3 +Treatment 1 µm Tumor cells Tumor cells + Treatment 1 µm Co-culture +DMSO Co-culture+DMSO +anti-cd3 Co-culture +anti-cd3 +Inactive 1 µm Co-culture +anti-cd3 +Treatment 1 µm 16
17 Treatment modulates secretion of IL8 and GM-CSF 17 Co-culture IL8: Supports proliferation, survival and migration of cancer cells Associated with tumor-induced immune suppression Co-culture GM-CSF: Adjuvant in cancer vaccines: boosts antigen presentation by dendritic cells Generally considered immune stimulatory Context specific immune suppressive role in the tumor microenvironment
18 Do immune cells infiltrate? Tumor spheroids: Histology Light-sheet microscopy High content imaging ECM-embedded tumor cultures 3D bioprinting PE Opera Phenix 18
19 Treatment enhances recruitment of CD3+ cells to tumor spheroids OvCAR8/PBMC H&E 20x OvCAR8/PBMC CD3 20x OvCAR8/PBMC/Treatment H&E 20x OvCAR8/PBMC/Treatment CD3 20x 19
20 Treatment stimulates PBMC migration through tumors No treatment Treatment 10 µm 20
21 Pathology relevance of modeling tumors in vitro with ECM and stroma 21
22 Our approach along side traditional methods: light-based bio-printing 1. Mix cells + lightresponsive biomatrix 2. Apply light-mask to polymerize biomatrix at micrometer scale 3. Wash out free cells; a precise cellular construct is obtained 22
23 PBMC migrate through a novel pathology relevant bioink Day1 Day2 Day3 OvCar8-mCherry PBMC 20x magnification Maximal projection 23
24 On going drug discovery efforts Expanding co-culture from a semi-automated to a fully automated assay Profiling pre-clinical candidates and clinical therapies in co-culture using different dosing strategies Evaluating phenotype of anti-pd1 therapy and combinations Developing an imaging-based immune cell infiltration assay 24
25 Acknowledgements Oncology Steve Kovats Ye Wang Bhavesh Pant Tamara Gilbert LeighAnn Alexander Lesley Griner Serena Silver Shumei Liu Kathy Hsiao Ying-Nan Chen Immuno-oncology Wei Guan Beatriz Perez Bill Hastings Glenn Dranoff Analytical Sciences &Imaging Christina Dornelas Farid SariSarraf Ned Kirkpatrick Ophthalmology Xin Qu Arnaud Lacoste Preclinical Safety Joyce Judge Keith Mansfield 25
Tumor Microenvironment and Immune Suppression
Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation
More informationDISCOVER MORE WITH LESS SAMPLE. nanostring.com/3d
nanostring.com/3d DISCOVER MORE WITH LESS SAMPLE. WHY COMPROMISE? ncounter Vantage ASSAYS POWERED BY 3D BIOLOGY TECHNOLOGY Don t let sample volume limit your analytical aspirations. Quantify DNA, RNA,
More informationCytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression
Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression Jarad J Wilson, Ph.D. Technical Support & Marketing Specialist Ruo-Pan Huang, MD, Ph.D. Founder and CEO What are Antibody Arrays?
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationDetection of immune cell checkpoint and functional markers in the tumor microenvironment by the RNA in situ hybridization RNAscope assay
pplication Note Immunotherapy Detection of immune cell checkpoint and functional markers in the tumor microenvironment by the RN in situ hybridization RNscope assay Ming-Xiao He, Na Li, Courtney nderson,
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationSUPPLEMENTARY FIGURES
SUPPLEMENTARY FIGURES Supplementary Figure S1: Fibroblast-induced elongation of cancer cells requires direct contact with living fibroblasts. A. Representative images of HT29-GFP cultured in the presence
More informationTherapeutic efficacy of MUC1- specific CTL and CD137 costimulation. mammary cancer model. Pinku Mukherjee & Sandra Gendler
Therapeutic efficacy of MUC1- specific CTL and CD137 costimulation in a spontaneous mammary cancer model Pinku Mukherjee & Sandra Gendler Goal of Immunotherapy Boosting the low level anti-tumor immune
More informationSupplementary information. Characterization of c-maf + Foxp3 - Regulatory T Cells Induced by. Repeated Stimulation of Antigen-Presenting B Cells
Chien 1 Supplementary information Manuscript: SREP-16-42480A Characterization of c-maf + Foxp3 - Regulatory T Cells Induced by Repeated Stimulation of Antigen-Presenting B Cells Chien-Hui Chien 1, Hui-Chieh
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationCD90 + Human Dermal Stromal Cells Are Potent Inducers of FoxP3 + Regulatory T Cells
CD90 + Human Dermal Stromal Cells Are Potent Inducers of FoxP3 + Regulatory T Cells Karin Pfisterer, Karoline M Lipnik, Erhard Hofer and Adelheid Elbe-Bürger Journal of Investigative Dermatology (2015)
More informationBioassays for Quality Control of Cell & Gene Therapy Products
Bioassays for Quality Control of Cell & Gene Therapy Products Erik Rutjens, Cell & Gene Therapy, Novartis Pharma AG CASSS Bioassays, Silver Spring, March2015 CTL019 Introduction CARTs = Chimeric Antigen
More informationOptimizing Intracellular Flow Cytometry:
Optimizing Intracellular Flow Cytometry: Simultaneous Detection of Cytokines and Transcription Factors Presented by Jurg Rohrer, PhD, BD Biosciences 23-10780-00 Outline Introduction Cytokines Transcription
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationOptimizing Intracellular Flow Cytometry:
Optimizing Intracellular Flow Cytometry: Simultaneous Detection of Cytokines and Transcription Factors An encore presentation by Jurg Rohrer, PhD, BD Biosciences 10.26.10 Outline Introduction Cytokines
More informationBases for Immunotherapy in Multiple Myeloma
Bases for Immunotherapy in Multiple Myeloma Paola Neri, MD, PhD Associate Professor of Medicine University of Calgary, Arnie Charbonneau Cancer Institute Disclosures Paola Neri MD, PhD Grants/research
More informationInnate and Cellular Immunology Control of Infection by Cell-mediated Immunity
Innate & adaptive Immunity Innate and Cellular Immunology Control of Infection by Cell-mediated Immunity Helen Horton PhD Seattle Biomedical Research Institute Depts of Global Health & Medicine, UW Cellular
More informationDISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding
DISCLOSURES Roche/MSD-Merck/Celgene: Research Funding Roche/Celgene/AstraZeneca/Amgen/MSD/Novartis/Sanofi- Aventis/Pierre Fabré: Advisory Board or Consultant No conflict of interest with respect to this
More informationTumor Associated Macrophages as a Novel Target for Cancer Therapy
Tumor mass Tumor Associated Macrophage Tumor Associated Macrophages as a Novel Target for Cancer Therapy This booklet contains forward-looking statements that are based on Amgen s current expectations
More informationAnti-inflammatory properties of SM04690, a small molecule inhibitor of the Wnt pathway as a potential treatment for knee osteoarthritis
Anti-inflammatory properties of SM04690, a small molecule inhibitor of the Wnt pathway as a potential treatment for knee osteoarthritis V. Deshmukh 1, T. Seo 1, C. Swearingen 1, Y. Yazici 1 1 Samumed,
More informationEngineering an in vitro human immune system for rapid vaccine evaluation
Engineering an in vitro human immune system for rapid vaccine evaluation William Warren, Ph.D. VaxDesign Corporation Orlando, FL 32826 wwarren@vaxdesign.com www.vaxdesign.com 1 MIMIC Technology Overview
More informationCD4 + CD25 high Foxp3 + T regulatory cells kill autologous CD8(+) and CD4(+) T cells using Fas/FasL- and Granzyme B- mediated pathways
CD4 + CD25 high Foxp3 + T regulatory cells kill autologous CD8(+) and CD4(+) T cells using Fas/FasL- and Granzyme B- mediated pathways Laura Strauss, Christoph Bergmann, Theresa L. Whiteside University
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationSupplementary Figure 1. Deletion of Smad3 prevents B16F10 melanoma invasion and metastasis in a mouse s.c. tumor model.
A B16F1 s.c. Lung LN Distant lymph nodes Colon B B16F1 s.c. Supplementary Figure 1. Deletion of Smad3 prevents B16F1 melanoma invasion and metastasis in a mouse s.c. tumor model. Highly invasive growth
More informationNK cell flow cytometric assay In vivo DC viability and migration assay
NK cell flow cytometric assay 6 NK cells were purified, by negative selection with the NK Cell Isolation Kit (Miltenyi iotec), from spleen and lymph nodes of 6 RAG1KO mice, injected the day before with
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationDefective STAT1 activation associated with impaired IFN-g production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2
Defective STAT1 activation associated with impaired IFN-g production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2 SUPPLEMENTARY FIGURES AND TABLES Supplementary Figure S1:
More informationAntiangiogenesis - Immune Therapy Combinations. George Coukos, MD, PhD Heinz Zwierzina, MD
Antiangiogenesis - Immune Therapy Combinations George Coukos, MD, PhD Heinz Zwierzina, MD Overview Effect of VEGF on antitumor immune response Antigen presentation Effector mechanisms Ying and yang and
More informationPD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs
PD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs Steven Dow, DVM, PhD Department of Clinical Sciences, Animal Cancer Center Colorado State University Consortium
More informationChallenges)facing)An./tumour) Immunotherapy)in)Myeloma)))
Challenges)facing)An./tumour) Immunotherapy)in)Myeloma))) Immune Dysfunction Prof)Gordon)Cook) Leeds)Ins.tute)of)Cancer)&)Pathology) University)of)Leeds) Impaired)immunity)in)MM) )clinical) % of Infection-related
More informationUsing AlphaLISA Biomarker Kits to Assess Effects of PBMC-Conditioned Media on 3D and 2D Cell Culture Models of Breast Cancer
APPLIATION NOTE AlphaLISA Technology Authors: Jeanine Hinterneder Jen arlstrom Adam arlson awn Nida PerkinElmer, Inc. Hopkinton, MA Using AlphaLISA iomarker Kits to Assess Effects of PM-onditioned Media
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationReporter Gene Immunotherapy Bioassays
Reporter Gene Immunotherapy Bioassays Expand the Tool Box for Drug Development in Individual and Combination Immunotherapy Jey Cheng, Ph.D. 215. BEBPA Bioassay Conference September 3, 216 Presentation
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationCYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION
CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION What is Cytokine? Secreted popypeptide (protein) involved in cell-to-cell signaling. Acts in paracrine or autocrine fashion through specific cellular receptors.
More informationGeneration of monocytederived Dendritic Cells (modcs)
monocytederived Dendritic (modcs) Application Note Background Dendritic (DCs) are so called because of their characteristic cell surface projections that resemble the dendrites of neurons (see Fig 1 and
More informationMECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW
MECHANISMS OF CELLULAR REJECTION IN ORGAN TRANSPLANTATION AN OVERVIEW YVON LEBRANCHU Service Néphrologie et Immunologie Clinique CHU TOURS ANTIGEN PRESENTING CELL CD4 + T CELL CYTOKINE PRODUCTION CLONAL
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationNKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity
NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity Peiwen Kuo Scientist, Research Biology Nektar Therapeutics August 31 st, 2018 Emerging
More informationUsing Multiplex Assays and Assay Development to Enhance your Research Program James A. Lederer, PhD
Using Multiplex Assays and Assay Development to Enhance your Research Program James A. Lederer, PhD Department of Surgery Brigham and Women s Hospital (BWH), BWH Biomedical Research Institute (BWH-BRI)
More informationSupplementary Information:
Supplementary Information: Follicular regulatory T cells with Bcl6 expression suppress germinal center reactions by Yeonseok Chung, Shinya Tanaka, Fuliang Chu, Roza Nurieva, Gustavo J. Martinez, Seema
More informationASTARTE IN ACTION. Using a Recall Antigen Assay as a Tool for Understanding Immunity CASE STUDY
ASTARTE IN ACTION Using a Recall Antigen Assay as a Tool for Understanding Immunity CASE STUDY Introduction While there is no industry-accepted protocol for measuring the functionality of peripheral blood
More informationExcerpt from MACS&more Vol 17 1/2016. Kenji Miki¹, Koji Nagaoka¹, Hermann Bohnenkamp², Takayuki Yoshimoto³, Ryuji Maekawa¹*, and Takashi Kamigaki⁴
Excerpt from MCS&more Vol 17 1/2016 Dendritic cells pulsed with induce both OV-specific CD4 + and CD8 + T cells and cause antitumor effects in a mouse model of lymphoma Kenji Miki¹, Koji Nagaoka¹, Hermann
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationTumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14 + PD-L1 + phenotype in prostate cancer
OncoImmunology ISSN: (Print) 2162-402X (Online) Journal homepage: https://www.tandfonline.com/loi/koni20 Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive
More informationWhat Information Provided by Models Inform Immune Drug Development and Use? Philip Gotwals Executive Director, Exploratory Immuno-Oncology Novartis
What Information Provided by Models Inform Immune Drug Development and Use? Philip Gotwals Executive Director, Exploratory Immuno-Oncology Novartis Institutes for Biomedical Research SITC, 2016 National
More informationSupplemental Figure 1. IL-3 blockade with Fab CSL362 depletes plasmacytoid dendritic cells (pdcs), but not basophils, at higher doses.
Supplemental Figure 1. IL-3 blockade with Fab CSL362 depletes plasmacytoid dendritic cells (pdcs), but not basophils, at higher doses. Percentage of viable (A) pdcs (Sytox Blue-, Lin1-, HLADR+, BDCA2++)
More informationContribution of microglia to tissue injury and repair in MS
Contribution of microglia to tissue injury and repair in MS MS disease course histologic features Courtesy of Samuel Ludwin I ACUTE CHRONIC s ACTIVE CHRONIC Clinical Course Intra CNS Extra CNS Imaging
More informationCytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands
Cytotoxicity assays Rory D. de Vries, PhD 1 1 Viroscience lab, Erasmus MC, Rotterdam, the Netherlands Anti-influenza immunity Humoral / CD4+ / CD8+ / NK? Function of CTL Elimination of virus-infected cells?
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationEnhanced Cancer Vaccine Effectiveness with NKTR-214, a CD122-Biased Cytokine
Enhanced Cancer Vaccine Effectiveness with NKTR-214, a CD122-Biased Cytokine Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics SMI Cancer Vaccines, September 2017 Nektar Therapeutics
More informationT cell-mediated immunity
T cell-mediated immunity Overview For microbes within phagosomes in phagocytes.cd4+ T lymphocytes (TH1) Activate phagocyte by cytokines studies on Listeria monocytogenes For microbes infecting and replicating
More informationNKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
More informationACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY
ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY The recognition of specific antigen by naïve T cell induces its own activation and effector phases. T helper cells recognize peptide antigens through
More informationSUPPLEMENT Supplementary Figure 1: (A) (B)
SUPPLEMENT Supplementary Figure 1: CD4 + naïve effector T cells (CD4 effector) were labeled with CFSE, stimulated with α-cd2/cd3/cd28 coated beads (at 2 beads/cell) and cultured alone or cocultured with
More informationDesign and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways
Design and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways Shihua Lin, PhD. Senior Scientist Analytical Biotechnology Development, MedImmune
More informationCD14 + S100A9 + Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer
CD14 + S1A9 + Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer Po-Hao, Feng M.D., Kang-Yun, Lee, M.D. Ph.D., Ya-Ling Chang, Yao-Fei Chan, Lu- Wei, Kuo,Ting-Yu
More informationAge-Related Changes in Immune System Function. Professor Justin Hall October 12, 2010
Age-Related Changes in Immune System Function Professor Justin Hall October 12, 2010 Immune Function: Effect of Aging and Exercise Why study this? INCREASED RISK for infectious diseases, tumorigenesis,
More informationCytokines, adhesion molecules and apoptosis markers. A comprehensive product line for human and veterinary ELISAs
Cytokines, adhesion molecules and apoptosis markers A comprehensive product line for human and veterinary ELISAs IBL International s cytokine product line... is extremely comprehensive. The assays are
More informationNKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology
plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics World Preclinical Congress, 2017
More informationNeutrophils contribute to fracture healing by synthesizing fibronectin+ extracellular matrix rapidly after injury
Neutrophils contribute to fracture healing by synthesizing fibronectin+ extracellular matrix rapidly after injury Bastian OW, Koenderman L, Alblas J, Leenen LPH, Blokhuis TJ. Neutrophils contribute to
More informationThe Immune Response in Time and Space
The Immune Response in Time and Space Chapters 14 & 4 Sharon S. Evans, Ph.D. Department of Immunology 845-3421 sharon.evans@roswellpark.org September 18 & 23, 2014 Inflammation Inflammation Complex response
More informationRole of Inflammatory and Progenitor Cells in Pulmonary Vascular Remodeling: Potential Role for Targeted Therapies. Traditional Hypothesis Stress
3/1/212 Role of Inflammatory and Progenitor Cells in Pulmonary Vascular Remodeling: Potential Role for Targeted Therapies K.R. Stenmark University of Colorado Denver, CO 845 Prominent Fibroproliferative
More informationHuman and mouse T cell regulation mediated by soluble CD52 interaction with Siglec-10. Esther Bandala-Sanchez, Yuxia Zhang, Simone Reinwald,
Human and mouse T cell regulation mediated by soluble CD52 interaction with Siglec-1 Esther Bandala-Sanchez, Yuxia Zhang, Simone Reinwald, James A. Dromey, Bo Han Lee, Junyan Qian, Ralph M Böhmer and Leonard
More informationNANO 243/CENG 207 Course Use Only
L4: Nanomedicine in Immunotherapy April 12, 2018 Branches of the Immune System Body has two main branches of immunity, innate and adaptive. Innate immunity is the first line of defense. Phagocytes such
More informationFish Skin Grafts Promote Superior Cell Ingrowth Compared to Amnion Allografts, Human Cadaver Skin and Mammalian Extracellular Matrix (ECM)
Fish Skin Grafts Promote Superior Cell Ingrowth Compared to Amnion Allografts, Human Cadaver Skin and Mammalian Extracellular Matrix (ECM) Christopher L. Winters, DPM American Health Network Indianapolis,
More informationRegulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.
Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationHuman mesenchymal stromal cells (MSCs) can potently
Morphological features of IFN-γ stimulated mesenchymal stromal cells predict overall immunosuppressive capacity Matthew W. Klinker a,1, Ross A. Marklein a,1, Jessica L. Lo Surdo a, Cheng-Hong Wei a, and
More informationTrevigen s Extracellular Matrix Proteins for Triculture of Breast Cancer Spheroids, Endothelial Tubules, and Human Mesenchymal Stem Cells
Trevigen s Extracellular Matrix Proteins for Triculture of Breast Cancer Spheroids, Endothelial Tubules, and Human Mesenchymal Stem Cells Gabriel Benton, Ph.D. and Jay George, Ph.D., Trevigen, Inc. Gaithersburg,
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): In the manuscript Rational Combination of CXCL11-Expressing Oncolytic Virus and PD-L1 Blockade Works Synergistically to Enhance Therapeutic Efficacy
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationExosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signalling pathway
Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signalling pathway Jieyuan Zhang, Xiaolin Liu, Haiyan Li, Chunyuan Chen, Bin Hu, Xin Niu, Qing
More informationMeasuring Dendritic Cells
Measuring Dendritic Cells A.D. Donnenberg, V.S. Donnenberg UNIVERSITY of PITTSBURGH CANCER INSTITUTE CCS Longbeach 10_04 Measuring DC Rare event detection The basics of DC measurement Applications Cancer
More informationHuman CD4+T Cell Care Manual
Human CD4+T Cell Care Manual INSTRUCTION MANUAL ZBM0067.04 SHIPPING CONDITIONS Human CD4+T Cells, cryopreserved Cryopreserved human CD4+T cells are shipped on dry ice and should be stored in liquid nitrogen
More informationQuantitative PPARγ expression affects the balance between tolerance and immunity
Quantitative PPARγ expression affects the balance between tolerance and immunity Ya-Hui Liu 1, Yau-Sheng Tsai 1,2,3, Shih-Chieh Lin 4, Nan-Shih Liao 5, Ming-Shiou Jan 6, Chung-Tiang Liang 7, Shih-Wen Hsu
More informationAssays for Immuno-oncology Research Real-time automated measurements of immune and tumor cell dynamics within your incubator
INCUCYTE LIVE-CELL ANALYSIS SYSTEM Assays for Immuno-oncology Research Real-time automated measurements of immune and tumor cell dynamics within your incubator See what your cells are doing and when they
More informationΑνοσολογικοί μηχανισμοί στην ανοσοθεραπεία καρκίνου
Ανοσολογικοί μηχανισμοί στην ανοσοθεραπεία καρκίνου Verginis Panos Ph.D. Assistant Professor Level Laboratory of Immune Regulation and Tolerance Biomedical Research Foundation Academy of Athens, Greece
More informationOverview of methodology, tools and reagents for evaluating cell proliferation and invasion using multicellular tumor spheroids.
The Next Step in the Evolution of 3D Culture: Utilizing Extracellular Matrix to Enhance Multicellular Tumor Spheroid Models for Proliferation and Invasion Overview of methodology, tools and reagents for
More informationWelcome. Nanostring Immuno-Oncology Summit. September 21st, FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Welcome Nanostring Immuno-Oncology Summit September 21st, 2017 1 FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. FOR RESEARCH USE ONLY. Not for use in diagnostic procedures. Agenda 4:00-4:30
More informationIdentification of synoviocyte activation. Deborah Nguyen Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121
Identification of synoviocyte activation inhibitors by parallel biomarker profiling Deborah Nguyen Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121 1 GNF Paradigm for Discovery
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy
More informationIn Vitro and Ex Vivo Immuno- Oncology Drug Discovery
Oncology Drug Discovery CrownBio s integrated Immuno-Oncology Platform allows end-to-end in vitro and ex vivo immunoprofiling, functional assay evaluation, and novel target validation Discover how CrownBio
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationPBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human
Anti-CD19-CAR transduced T-cell preparation PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human AB serum (Gemini) and 300 international units/ml IL-2 (Novartis). T cell proliferation
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationEx vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2*
Ex vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2* 1 Department of Laboratory Medicine - Laboratory of Hematology, Radboud University
More informationLong-term consumption of Carnosine contributes to improving effector functions of NK cells
International Journal of Science Vol.5 No.7 218 ISSN: 1813-489 Long-term consumption of arnosine contributes to improving effector functions of NK cells bstract Guangao Liu ollege of Life Science and Technology,
More informationReview Questions: Janeway s Immunobiology 8th Edition by Kenneth Murphy
Review Questions: Janeway s Immunobiology 8th Edition by Kenneth Murphy Chapter 11 (pages 429-460): Dynamics of Adaptive Immunity prepared by Kelly von Elten, Walter Reed National Military Medical Center,
More informationREPROGRAMING IMMUNITY IN RENAL CELL CARCINOMA
REPROGRAMING IMMUNITY IN RENAL CELL CARCINOMA RETHINKING TYROSINE KINASE INHIBITORS Dr. L.M. Antón Aparicio. Complejo Universitario de La Coruña INTRODUCTION Angiogenesis, which is regulated by a fine
More informationThe Good, the Bad and the Ugly: Clinical trials which assess vaccine characteristics. ISBT Meeting, San Francisco, CA November 4-8, 2004
The Good, the Bad and the Ugly: Clinical trials which assess vaccine characteristics ISBT Meeting, San Francisco, CA November 4-8, 2004 Ideal cancer vaccine trial 1. An informative immune assay 2. Ability
More informationGBR 1302: EFFECT OF CD3-HER2, A BISPECIFIC T CELL ENGAGER ANTIBODY, IN TRASTUZUMAB-RESISTANT CANCERS
GBR 1302: EFFECT OF CD3-HER2, A BISPECIFIC T CELL ENGAGER ANTIBODY, IN TRASTUZUMAB-RESISTANT CANCERS JONATHAN BACK 1 ; MARTIN WERMKE 2 ; JULIE MACOIN 1 ; AMELIE CROSET 1 ; JOHN KAUH 3 ; VENKATESHWAR REDDY
More informationof whole cell cultures in U-bottomed wells of a 96-well plate are shown. 2
Supplementary online material Supplementary figure legends Supplementary Figure 1 Exposure to T reg cells causes loss of T resp cells in co-cultures. T resp cells were stimulated with CD3+CD28 alone or
More informationPart III Innate and Adaptive Immune Cells: General Introduction
Innate and Adaptive Immune Cells: General Introduction Iván López-Expósito As an organ specialized in food digestion and nutrient absorption, the intestinal mucosa presents a huge surface area (almost
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationSupplementary Figure 1
Supplementary Figure 1 Identification of IFN-γ-producing CD8 + and CD4 + T cells with naive phenotype by alternative gating and sample-processing strategies. a. Contour 5% probability plots show definition
More informationPRIME-XV Dendritic Cell Maturation CDM
PRIME-XV Dendritic Cell Maturation CDM Chemically defined, animal component-free medium for dendritic cell culture Optimized for differentiation of monocytes into immature dendritic cells (idcs) and subsequent
More informationSupplementary Figure 1. Example of gating strategy
Supplementary Figure 1. Example of gating strategy Legend Supplementary Figure 1: First, gating is performed to include only single cells (singlets) (A) and CD3+ cells (B). After gating on the lymphocyte
More informationsupplementary information
DOI: 10.1038/ncb2133 Figure S1 Actomyosin organisation in human squamous cell carcinoma. (a) Three examples of actomyosin organisation around the edges of squamous cell carcinoma biopsies are shown. Myosin
More informationTargeting tumour associated macrophages in anti-cancer therapies. Annamaria Gal Seminar Series on Drug Discovery Budapest 5 January 2018
Targeting tumour associated macrophages in anti-cancer therapies Annamaria Gal Seminar Series on Drug Discovery Budapest 5 January 2018 Macrophages: Professional phagocytes of the myeloid lineage APC,
More information